597 related articles for article (PubMed ID: 27498345)
1. Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril Formation in an In Vivo RDEB Model.
Turczynski S; Titeux M; Tonasso L; Décha A; Ishida-Yamamoto A; Hovnanian A
J Invest Dermatol; 2016 Dec; 136(12):2387-2395. PubMed ID: 27498345
[TBL] [Abstract][Full Text] [Related]
2. Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations.
McGrath JA; Ashton GH; Mellerio JE; Salas-Alanis JC; Swensson O; McMillan JR; Eady RA
J Invest Dermatol; 1999 Sep; 113(3):314-21. PubMed ID: 10469327
[TBL] [Abstract][Full Text] [Related]
3. Compound heterozygosity for a recessive glycine substitution and a splice site mutation in the COL7A1 gene causes an unusually mild form of localized recessive dystrophic epidermolysis bullosa.
Terracina M; Posteraro P; Schubert M; Sonego G; Atzori F; Zambruno G; Bruckner-Tuderman L; Castiglia D
J Invest Dermatol; 1998 Nov; 111(5):744-50. PubMed ID: 9804332
[TBL] [Abstract][Full Text] [Related]
4. Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients.
Goto M; Sawamura D; Nishie W; Sakai K; McMillan JR; Akiyama M; Shimizu H
J Invest Dermatol; 2006 Dec; 126(12):2614-20. PubMed ID: 16778792
[TBL] [Abstract][Full Text] [Related]
5. Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa.
Berthault C; Gaucher S; Gouin O; Schmitt A; Chen M; Woodley D; Titeux M; Hovnanian A; Izmiryan A
J Invest Dermatol; 2024 Jun; 144(6):1322-1333.e13. PubMed ID: 38043638
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy.
Bornert O; Kühl T; Bremer J; van den Akker PC; Pasmooij AM; Nyström A
Mol Ther; 2016 Aug; 24(7):1302-11. PubMed ID: 27157667
[TBL] [Abstract][Full Text] [Related]
7. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa.
Chen M; Kasahara N; Keene DR; Chan L; Hoeffler WK; Finlay D; Barcova M; Cannon PM; Mazurek C; Woodley DT
Nat Genet; 2002 Dec; 32(4):670-5. PubMed ID: 12426566
[TBL] [Abstract][Full Text] [Related]
8. Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.
Jacków J; Titeux M; Portier S; Charbonnier S; Ganier C; Gaucher S; Hovnanian A
J Invest Dermatol; 2016 Jul; 136(7):1346-1354. PubMed ID: 26994967
[TBL] [Abstract][Full Text] [Related]
9. Antisense-mediated exon skipping to reframe transcripts.
Turczynski S; Titeux M; Pironon N; Hovnanian A
Methods Mol Biol; 2012; 867():221-38. PubMed ID: 22454065
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Models for the Evaluation of Antisense Oligonucleotides in Skin.
Bremer J; van den Akker PC
Methods Mol Biol; 2022; 2434():185-190. PubMed ID: 35213017
[TBL] [Abstract][Full Text] [Related]
11. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
Bornert O; Hogervorst M; Nauroy P; Bischof J; Swildens J; Athanasiou I; Tufa SF; Keene DR; Kiritsi D; Hainzl S; Murauer EM; Marinkovich MP; Platenburg G; Hausser I; Wally V; Ritsema T; Koller U; Haisma EM; Nyström A
J Invest Dermatol; 2021 Apr; 141(4):883-893.e6. PubMed ID: 32946877
[TBL] [Abstract][Full Text] [Related]
12. Collagen VII Expression Is Required in Both Keratinocytes and Fibroblasts for Anchoring Fibril Formation in Bilayer Engineered Skin Substitutes.
Supp DM; Hahn JM; Combs KA; McFarland KL; Schwentker A; Boissy RE; Boyce ST; Powell HM; Lucky AW
Cell Transplant; 2019; 28(9-10):1242-1256. PubMed ID: 31271052
[TBL] [Abstract][Full Text] [Related]
13. An RNA-targeted therapy for dystrophic epidermolysis bullosa.
Peking P; Koller U; Duarte B; Murillas R; Wolf S; Maetzig T; Rothe M; Kocher T; García M; Brachtl G; Schambach A; Larcher F; Reichelt J; Bauer JW; Murauer EM
Nucleic Acids Res; 2017 Sep; 45(17):10259-10269. PubMed ID: 28973459
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients with recessive dystrophic epidermolysis bullosa in the Netherlands: expansion of the mutation database and unusual phenotype-genotype correlations.
van den Akker PC; van Essen AJ; Kraak MM; Meijer R; Nijenhuis M; Meijer G; Hofstra RM; Pas HH; Scheffer H; Jonkman MF
J Dermatol Sci; 2009 Oct; 56(1):9-18. PubMed ID: 19665875
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological correlations of compound heterozygous COL7A1 mutations in recessive dystrophic epidermolysis bullosa.
Dunnill MG; McGrath JA; Richards AJ; Christiano AM; Uitto J; Pope FM; Eady RA
J Invest Dermatol; 1996 Aug; 107(2):171-7. PubMed ID: 8757758
[TBL] [Abstract][Full Text] [Related]
16. Exon 87 skipping of the COL7A1 gene in dominant dystrophic epidermolysis bullosa.
Koga H; Hamada T; Ishii N; Fukuda S; Sakaguchi S; Nakano H; Tamai K; Sawamura D; Hashimoto T
J Dermatol; 2011 May; 38(5):489-92. PubMed ID: 21352278
[TBL] [Abstract][Full Text] [Related]
17. Characterization of 18 new mutations in COL7A1 in recessive dystrophic epidermolysis bullosa provides evidence for distinct molecular mechanisms underlying defective anchoring fibril formation.
Hovnanian A; Rochat A; Bodemer C; Petit E; Rivers CA; Prost C; Fraitag S; Christiano AM; Uitto J; Lathrop M; Barrandon Y; de Prost Y
Am J Hum Genet; 1997 Sep; 61(3):599-610. PubMed ID: 9326325
[TBL] [Abstract][Full Text] [Related]
18. Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes.
Latella MC; Cocchiarella F; De Rosa L; Turchiano G; Gonçalves MAFV; Larcher F; De Luca M; Recchia A
J Invest Dermatol; 2017 Apr; 137(4):836-844. PubMed ID: 28027893
[TBL] [Abstract][Full Text] [Related]
19. Splicing Modulation via Antisense Oligonucleotides in Recessive Dystrophic Epidermolysis Bullosa.
Hainzl S; Trattner L; Liemberger B; Bischof J; Kocher T; Ablinger M; Nyström A; Obermayer A; Klausegger A; Guttmann-Gruber C; Wally V; Bauer JW; Hofbauer JP; Koller U
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255836
[TBL] [Abstract][Full Text] [Related]
20. COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa.
Hainzl S; Peking P; Kocher T; Murauer EM; Larcher F; Del Rio M; Duarte B; Steiner M; Klausegger A; Bauer JW; Reichelt J; Koller U
Mol Ther; 2017 Nov; 25(11):2573-2584. PubMed ID: 28800953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
